Dean Watzman, MD
Pulmonary Disease · Beaver, PANPI 1497738967
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.3%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Olympus Corporation Of The Americas at 43.8% of the total. Reporting peaked in 2024 at $1,249 and has fallen 82.7% since, to $216 in 2025.
Across 122 payments — averaging $38.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- GSK$1K
- AstraZeneca$250
- Boehringer Ingelheim$232
- Sanofi$162
- Pfizer$134
- plus $492 from 16 others
What the payments were for
- Consulting fees$1403%
- Travel & lodging$1,88640%
- Food & beverage$2,63056%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 21 | $2,045 |
| GSK | 42 | $1,352 |
| AstraZeneca | 9 | $250 |
| Boehringer Ingelheim | 18 | $232 |
| Sanofi | 3 | $162 |
| Pfizer | 2 | $134 |
| Regeneron Healthcare Solutions, Inc. | 4 | $86 |
| Gilead | 4 | $55 |
| Shire North American Group Inc | 2 | $40 |
| Philips North America LLC | 2 | $40 |
| Grifols USA, LLC | 2 | $39 |
| Insmed, Inc. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Merck | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINGLE USE SUCTION VALVE (Sterile)$724
- NUCALA$558
- Single Use Guide Sheath Kit$399
- TRELEGY ELLIPTA$125
- DUPIXENT$125
- ANORO$125
- TEZSPIRE$124
- ELIQUIS$120
How this compares
$4,668 in reported general payments places this provider in the 70th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Beaver
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.